The Medtech Supply Chain is Being Tested: Here’s What the Data Says

Medtech supply chain leaders are used to operating under pressure. Regulatory scrutiny, design complexity, and the high stakes of patient safety mean this industry has always demanded more from its manufacturing and sourcing operations. But this year, the pressure has compounded. Cost volatility, geographic realignment, accelerating technology adoption, and rising supplier performance expectations are converging, and they’re hitting just as program timelines and quality standards remain non-negotiable.

Fictiv’s 2026 State of Manufacturing and Supply Chain Report surveyed hundreds of manufacturing and supply chain leaders across industries. A closer look at the medtech findings reveals several trends that warrant serious attention. None of them are shocking, but together, they paint a very telling picture. 

Material Cost Pressure Forces a Sourcing Strategy Rethink

One of the report’s most revealing findings is that 98% of manufacturing leaders are experiencing material cost pressure, which means virtually no one is currently operating in a stable cost environment. For medtech specifically, 90% of leaders said raw material costs are actively impacting their sourcing strategies.

That figure carries particular weight in this sector, and most medtech leaders reading it will likely feel it immediately. These companies have historically prioritized supply stability and regulatory continuity above almost everything else, and for good reason. Switching a material or a supplier isn’t a procurement decision that can be made on a whim. It touches design history files, validation protocols, and potentially a U.S. Food and Drug Administration 510(k) or PMA submission. The friction is real. The fact that 90% of medtech leaders are adjusting their sourcing strategies shows how significant this pressure has become—enough to absorb that friction rather than absorb the cost.

What this demands, practically speaking, is a shift in how companies think about supply chain optionality. Pre-qualified alternative materials and suppliers used to be a best practice reserved for the most risk-conscious organizations. In 2026, they look more like basic operational insurance. Companies that have conducted the upfront work to qualify alternative materials can absorb cost shocks without derailing schedules or triggering downstream quality events. Companies that haven’t done the work are facing those shocks in the worst possible sequence—reactive supplier switches mid-program, unplanned revalidation cycles, and everything that ripples out from there.

The mindset shift required here is significant, moving from locking in a bill of materials and treating sourcing as a closed question to maintaining living optionality as an ongoing supply chain discipline. That’s a different operating model, and building it takes time that companies acting reactively simply don’t have.

From product launches to M&A and manufacturing trends, the MPO Source delivers the medtech news you need twice a week. Subscribe here!

Why Medtech Should Lead the Reshoring Mandate 

Eighty-two percent of medtech companies in Fictiv’s survey are seeking to expand U.S.-based manufacturing. Across five years of Fictiv data, 2026 shows the strongest shift yet toward onshoring and regional production. This isn’t a cycle but rather a durable change in thinking about manufacturing geographies.

It’s worth noting where medtech onshoring plans sit compared with other sectors: EV companies are at 90%, climate tech is at 87%, and robotics is at 69%. Medtech’s 82% is high, but the reasons driving it are meaningfully different from what’s pushing other industries in the same direction. For EV and climate tech, much of the reshoring pressure is tied to tariff exposure and supply security for critical minerals. For medtech, the drivers are more structural: traceability requirements, audit-readiness, post-COVID institutional memory of the consequences of sourcing critical components from a single region, and the compounding pressure to iterate faster without sacrificing regulatory integrity.

The implications extend beyond any individual company’s sourcing decisions. Advanced domestic manufacturing capacity is finite, and the competition for it is intensifying simultaneously across industries. Medtech and climate tech don’t compete in the market, but they do compete at the supply chain level. That competition is going to shape lead times, pricing, and availability in ways the industry has not fully priced in yet.

The other piece of this picture is that onshoring isn’t a synonym for exclusively domestic. Regional hubs in Mexico, Canada, and Japan continue to play important complementary roles in a resilient manufacturing supply chain strategy. What the data actually demonstrates is a multi-region model, one where the U.S. anchor provides traceability and control, and regional partners provide flexibility, capacity overflow, and cost management. Building that network requires partners who already operate across those geographies.

AI is Moving From Pilot to Productivity Expectation 

Sixty percent of medtech leaders believe artificial intelligence (AI) will make them significantly more productive in manufacturing and supply chain operations, with a meaningful share expecting productivity gains at two to five times current levels. These aren’t modest expectations, and they’re being set in an industry that typically moves deliberately.

What’s particularly notable is where medtech leaders expect AI to have the most impact: 52% point to quality control and inspection as the primary application. That makes sense considering what quality failure actually costs in a regulated industry. A defect that escapes inspection isn’t just a rework problem. It’s a potential recall, a CAPA, a regulatory notification, and a hit to the quality system record that follows a product’s entire lifecycle.

In that context, AI-assisted inspection is a quality system investment and the opportunity extends upstream. AI embedded in design for manufacturability workflows can shift quality signals earlier in the development cycle, catching manufacturability risks and potential defect modes at the point when changes are still low-cost. The companies that will see the most meaningful ROI from AI won’t be those who deploy it as a standalone inspection tool but those who embed it across the design for manufacturing (DFM)-to-delivery workflow, using it to compress iteration loops, reduce NPI timelines, and surface risks before they become program problems.

So what will it take to realize those gains? Well, high expectations without measurement infrastructure (baselines, KPIs, honest feedback loops) erode quickly. The fastest gains will come from pairing AI with genuine workflow redesign, not from layering it onto already struggling processes. The technology can accelerate what’s working but it can’t substitute for the underlying operational model.

We’ve seen this play out with customers like TransMed7, which is commercializing breakthrough technologies for biopsy and cardiovascular intervention. By building the right digital manufacturing infrastructure early and prioritizing global access to regulated production, the company compressed a decade-long development timeline down to two. Companies that build the right manufacturing infrastructure early move faster and absorb disruption better than those trying to build that capacity mid-program.

Supplier Quality Metrics—the New Selection Standard

Fifty-seven percent of medtech leaders identify sourcing and capacity as the most important supplier quality metrics when selecting a manufacturing partner. On-time delivery performance and defect and corrective action records round out the picture. Taken together, what the data describes is a supplier selection process that is becoming increasingly data-backed and performance-driven rather than certification-driven.

Certifications matter, but they are increasingly the floor, not the standard. What medtech companies are signaling here is they want to see demonstrated, ongoing performance: i.e., real lead time data, real capacity transparency, real corrective action history. Not a quality manual and an audit checklist.

This has two important implications. First, manufacturing partners who can surface and share that data, and operate with genuine transparency into their own performance, will have a structural advantage in supplier selection. Partners who can’t, or won’t, will face increasing pressure as procurement teams move toward data-backed qualification. Second, in high-stakes programs like Class II and Class III devices, combination products, and implantables, transparency will outweigh unit price in supplier selection decisions. The cost of a quality escape downstream is simply too high for price to drive the decision when the performance data says otherwise.

The Bottom Line

Regional diversification is the new resilience. Pre-qualified alternatives, diversified regional networks, and documented contingency sourcing strategies are the infrastructure that keeps programs moving when the environment shifts. And in 2026, the environment will keep shifting. Companies that have built such an infrastructure will absorb the volatility whereas organizations that haven’t will spend the year reacting to it.

The onshoring intent documented in this report is real, but intent and execution are different things. Eighty-two percent of medtech companies want to expand U.S.-based manufacturing. The ones who will actually do it are those working with manufacturing partners who already have domestic capacity and established regional networks, not those who need to build from scratch while programs are in flight.

AI’s impact in medtech will be determined at the workflow level. The 60% of leaders expecting significant productivity gains are right to expect them—but those gains will be earned by organizations that embed AI into quality, DFM, and sourcing workflows with clear ownership, measurement, and adoption plans. Deployed carelessly, AI will produce pilots that don’t scale and expectations that erode.

The data in this year’s report is the clearest signal yet that medtech supply chains are being rebuilt instead of repaired. The question every leader should ask himself is a simple one: Where does your operation sit against these trends today, and where do the gaps create the most risk before the year is out?

More from this author: How Tariffs and Turbulence Are Accelerating Nearshoring in Medtech Manufacturing

Dave Evans is president and CEO of MISUMI Americas and co-founder of Fictiv.